A new model of the mechanism underlying lead poisoning: SNP in miRNA target region influence the AGT expression level

Yu Wu†, Miaomiao Wang‡, Jinlong Zhang‡, Na Sun‡ and Chunping Li‡*

Abstract

Background: To determine if the rs7079 polymorphism located in the 3′ UTR of the angiotensinogen gene (AGT) altered AGT gene expression and the risk of lead poisoning. A case-control study and luciferase reporter gene assay identified a significant association between rs7079 variants and the risk of lead poisoning.

Results: Serum AGT levels were significantly higher in individuals carrying the rs7079 CA genotype, as compared to those carrying the rs7079 CC genotype. The binding of the miRNA mimics miR-31-5p and miR-584-5p to the 3′ UTR of AGT differed based on which rs7079 variant was present, implying that AGT gene expression depends on the rs7079 variant carried.

Conclusions: The rs7079 C to A substitution reduced the binding of miR-31-5p/miR-584-5p to the 3′ UTR of AGT, possibly altering the risk of lead poisoning.

Keywords: Lead poisoning, 3′ untranslated region (3′ UTR), SNP, miRNA, AGT

Introduction

Lead is an important toxic agent that may be associated with population-level variations in cardiovascular disease rates [1]. Numerous population studies have shown that lead exposure can cause hypertension [2, 3]. However, the mechanisms involved in lead-induced hypertension remain to be clarified.

The renin-angiotensin-aldosterone system plays an important role in the regulation of blood pressure [4, 5]. Angiotensinogen (AGT), the initial substrate of the renin-angiotensin-aldosterone system pathway, is involved in the development of hypertension in humans and other animals [6, 7]. Animal studies have also shown that acute and chronic lead exposure cause hypertension and cardiovascular disease by altering the renin-angiotensin-aldosterone system: increasing angiotensin-converting enzyme activity [2, 8, 9], inhibiting Na⁺-K⁺-ATPase [10], inducing oxidative stress, reducing nitric oxide bioavailability, [11, 12] and depleting antioxidant reserves [13]. Many studies have provided new insights into the mechanisms by which lead can influence vascular function. Although these mechanisms have been proposed to explain lead-induced hypertension, its etiology remains unclear.

Polymorphisms in the AGT gene have significant effects on plasma AGT concentration, and are therefore involved in the pathogenesis of some diseases [6]. Su et al. [14] found that the rs7079 polymorphism was associated with blood pressure reduction in response to benazepril, while Ono et al. [15] showed that rs7079 might be a risk factor for non-alcoholic steatohepatitis. Al-Najai et al. [16] identified rs7079 as an independent risk factor for various deleterious cardiovascular traits. rs7079 has even been recognized as a factor in body fat distribution [17].

In addition, miRNAs often bind nucleotide sequences located in the 3′ Untranslated Region (UTR) of a given gene, modulating gene expression via post-transcriptional or post-translational mechanisms [18]. Because rs7079 is located on the 3′ UTR of the AGT gene, the AGT polymorphism might influence the binding of the miRNAs asIR-31 and miR-584 [19].
As lead exposure can increase blood pressure and AGT gene expression [2, 9], and the rs7079 polymorphism may affect AGT gene function, [19] it is possible that rs7079 may play a role in lead poisoning. However, the relationship between lead exposure and rs7079 has not previously been studied. Here, we hypothesized that the rs7079 variant in the AGT gene would be associated with lead poisoning. To test this hypothesis, we aimed to determine whether rs7079 might be associated with lead exposure in case-control study. We also aimed to determine whether the rs7079 polymorphism would influence the binding of the AGT 3′ UTR by miRNA.

Materials and methods

Study population

Our population-based case-control study included 304 individuals who had undergone a physical examination between 2012 and 2013 in Wuxi, China. Each participant completed a standardized questionnaire and signed a consent form. We drew 5 mL of blood from each participant, and used an atomic absorption spectrometer (AA800; Perkin-Elmer, Waltham, MA, USA) to detect blood lead levels (BLLs). BLLs were determined based on the National Occupational Health Standards of P. R. China, GBZ37–2002. Of the 304 participants, 114 individuals with blood lead levels (BLLs) ≥ 200 μL/L were considered lead poisoned (case group), while 190 individuals with BLLs < 200 μL/L were considered healthy (control group). The average lead concentration in production environment was 0.71 ± 0.43 mg/m³. Each individual in the case group reported at least 2 symptoms of lead toxicity, including headaches, nausea, gastritis, vomiting, lethargy, and poor appetite. Individuals who had smoked at least 1 cigarette per day for at least 1 year were defined as smokers, and individuals who consumed 3 or more alcoholic drinks per week for at least 1 year were considered drinkers [20]. All of our study protocols were approved by the Ethics Committee of Wuxi Center for Disease Control and Prevention.

Genotyping

We extracted genomic DNA from peripheral blood lymphocytes of all samples. Extracted DNA was dissolved in TE buffer. We genotyped the AGT gene using the TaqMan method on a Roche LC 480 Real-Time PCR system (Roche Diagnostics, Shanghai, China). The primer and probe sequences used are available from the authors upon request. Negative controls were included on each plate to ensure the accuracy of the genotyping. Genotyping was performed blindly and independently by at least two different researchers. Approximately 10% of all samples were randomly selected for genotype confirmation; both sets of results were 100% concordant.

Enzyme linked immunosorbent assay (ELISA)

We used a human AGT ELISA kit (Cusabio, Wuhan, China), which employs a quantitative sandwich enzyme immunoassay, to detect serum AGT levels in the case and control groups, following the manufacturer’s instructions. In brief, a microplate was pre-coated with an antibody specific to AGT. Standards and samples were pipetted into individual wells, such that all AGT was bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific to AGT was added. After washing, we added avidin-conjugated horseradish peroxidase to the wells. Following another wash to remove any unbound avidin-enzyme reagent, a substrate solution was added to the wells, which developed color in proportion to the amount of AGT bound in the initial step. After color development stopped, we measured the intensity of the color.

Plasmid construction and luciferase reporter assays

To construct luciferase reporter plasmids for the AGT 3′ UTR, we first amplified 613 bp fragments of the AGT 3′ UTR carrying the either the rs7079C or the rs7079A allele using PCR (forward primer: 5′- TCTAGCGGA TCGTCGAGGCGCAAGGCCCCAGACAC -3′ and reverse primer: 5′- TATTGGCGCCAGGCGCCGC GGAGGCTTTATTGCGCAACAGC -3′). For cloning purposes, the forward primer carried an Xho I restriction site at the 5′-end, and the reverse primer carried a Not I restriction site at the 3′-end. The amplified products were treated with the restriction enzymes Xho I and Not I. Finally, the amplified fragments carrying either the C or A allele were inserted into several cloning sites of the PDS131_psiCHECK-2 reporter plasmid. The plasmids containing C or A allele was conducted, respectively. These insertions were confirmed by sequencing.

We used functional luciferase assays to determine whether the miRNA mimics miR-31-5p and miR-584-5p affected AGT gene expression, and whether changes in AGT gene expression were influenced by the rs7079 polymorphism. For the luciferase reporter assay, HEK293 cells were placed in 24-well plates (8 × 10⁴ cells per well). Half of the cells were co-transfected with PDS131_psiCHECK-2-7079C and psiCHECK-2, and half with PDS131_psiCHECK-2-7079A and psiCHECK-2 (both at a ratio of 50:1). The transfected cells were then re-transfected with miR-31-5p, miR-584-5p, or a non-targeting miRNA (negative control; GenePharma, Shanghai, China) at a final concentration of 20 nmol/μL.

To test the effect of lead on miRNA binding, transfected HEK293 cells were treated with 5 μM lead acetate during the luciferase assay. We measured luciferase activity in HEK293 cell lysates 48 h post transfection with a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA), following the manufacturer’s instructions.
Luciferase activity was normalized against firefly luciferase. Each plasmid construct was evaluated independently in triplicate.

Statistical analyses
We used the $\chi^2$ test to evaluate differences among the frequency distributions of selected demographic variables, drinking status, and smoking status. We also used the $\chi^2$ test to compare the frequency distributions of each AGT allele and genotype between the case and control groups. We used multivariate logistic regressions to determine the adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Two-sided tests of statistical significance were conducted using SAS (version 9.1; SAS Institute, Inc., Cary, NC, USA).

Results
Demographic characteristics of the study population
There were no significant differences between the case and control groups with respect to age, sex, drinking status, and smoking status ($P > 0.05$ for all; Table 1). The mean age of the case individuals was 41.9 (± 7.4 years; range: 22–60), and the mean age of the control individuals was 40.7 (± 5.3 years; range: 22–62). The average BLL in the case group (548.53 ± 109.82 μg/L) was significantly higher than that of the controls (59.80 ± 42.40 μg/L; $P < 0.001$). Individuals in the case group had significantly higher systolic (132.47 ± 11.25 mmHg) and diastolic (86.12 ± 11.32 mmHg) blood pressures than did the controls (122.68 ± 13.36 and 81.03 ± 10.32 mmHg, respectively; $P < 0.001$).

| Variables       | BLL$^a$ (n = 190) | BLL$^b$ (n = 114) | $P^c$ |
|-----------------|--------------------|--------------------|-------|
| Age (y)         |                    |                    | 0.103 |
| $\leq$ 39       | 76                 | 40.0               | 35    | 30.7 |
| > 39            | 114                | 60.0               | 79    | 69.3 |
| Sex             |                    |                    | 0.062 |
| Male            | 119                | 62.6               | 59    | 51.7 |
| Female          | 71                 | 37.4               | 55    | 48.3 |
| Smoking status  |                    |                    | 0.126 |
| Smoker          | 65                 | 34.2               | 49    | 43.0 |
| Non-smoker      | 125                | 65.8               | 65    | 57.0 |
| Drinking status |                    |                    | 0.411 |
| Drinker         | 152                | 79.5               | 86    | 75.4 |
| Non-drinker     | 39                 | 20.5               | 28    | 24.6 |
| BLL (μg/L)      | 598.0 ± 42.40      | 548.53 ± 109.82    | < 0.001 |

* Blood lead level (BLL) < 200 μg/L
** Blood lead level (BLL) ≥ 400 μg/L
* Two-sided $\chi^2$ test

Genotypic distribution of the AGT polymorphisms
The rs7079 genotype frequencies in the control group were consistent with the Hardy-Weinberg equilibrium ($P = 0.329$; Table 2). The frequencies of the rs7079 polymorphisms CC, CA, and AA were significantly different between the control and case groups ($P = 0.04$ for all comparisons; Table 2). Moreover, a variant rs7079 genotype (CA or AA) appeared significantly more often in the case group (47.4%) than in the control group (33.3%; $P = 0.02$; Table 2). Thus, rs7079 variants CA and AA were associated with a significant risk of lead poisoning. Indeed, there was a significant association between individuals carrying either rs7079 CA or rs7079 AA and the risk of lead poisoning, relative to those carrying the rs7079 CC genotype (adjusted OR = 1.92, 95% CI = 1.16–3.18).

Our ELISA indicated that individuals carrying the rs7079 CC genotype had higher AGT serum concentrations than those carrying the CA genotype ($P = 0.01$; Fig. 1), suggesting that rs7079 was associated with AGT expression.

The rs7079A allele reduced 3′ UTR binding by miRNA
Transfection with either miR-31-5p or miR-584-5p significantly suppressed luciferase expression in the presence of the rs7079C allele but not in the presence of the rs7079A allele ($P < 0.05$; Fig. 2a). The suppressive effect of miR-584-5p was greater than that of miR-31-5p. miRNA binding in the presence of the rs7079 allele was unaffected. This suggested that the rs7079A variant affected the binding of miRNAs to the 3′ UTR of the AGT gene, and might ultimately influence AGT transcription or translation.

Lead had no direct effect on miRNA binding
Treatment with lead acetate slightly reduced the suppressive effect of miR-31-5p in the presence of the rs7079C allele, but did not affect miR-584-5p. miRNA binding in the presence of the rs7079A allele was also unaffected.

Discussion
Our major novel findings were as follows: 1) the AGT polymorphism rs7079 C was significantly associated with an increased risk of lead poisoning in a population from China; 2) the risk of lead poisoning was significantly higher in individuals carrying the AGT allele rs7079 A (genotypes rs7079 CA and rs7079 AA); 3) the presence of the AGT rs7079 A allele disrupted the binding of miR-31-5p and miR-584-5p to the 3′ UTR of AGT, and increased AGT gene expression, which is likely to reduce lead poisoning risk.

The epigenome may provide a suitable pathway by which lead exposure may influence disease susceptibility [21, 22]. Genetic analyses of polymorphisms in miRNA
target regions have become increasingly common [23]. However, this is the first study to examine the association between SNPs in the miRNA target region of the AGT gene and lead poisoning. Our results increase our understanding of the mechanisms by which AGT is involved in lead poisoning.

Lead exposure increases the risk of developing hypertension and other cardiovascular diseases [24]. AGT is an important regulator of blood pressure, and SNPs in the AGT gene are associated with increases in serum AGT levels and hypertension [6, 25–28]. In a previous study, we found that lead exposure increased blood pressure by increasing serum AGT [29]. In this study, we found the blood pressure in cases was higher than controls, although it had not arrived the level of hypertension. It might own to the “health worker effect” [30]. We found no direct association between blood pressure and rs7079 variant, however, it might indicate the complexity of mechanisms of lead poisoning.

Gene SNPs can be used to predict the toxicity of lead exposure [31, 32]. Here, rs7079 was significantly associated with the risk of lead poisoning, and individuals carrying the rs7079 A allele were at an increased risk of lead poisoning. Serum AGT concentrations were lower in individuals carrying the rs7079 C allele than in those carrying the rs7079 A allele, possibly because the rs7079 A allele decreases the binding between miRNAs and the AGT 3′ UTR. Therefore, our results suggested that rs7079 is a functional SNP, consistent with previous studies indicating that rs7079 was associated with non-alcoholic steatohepatitis [15], body fat distribution [17], and coronary artery disease [16].

Consistent with our results, a previous study used a luciferase reporter gene assay to show that the rs7079 A allele altered the binding of two miRNA mimics (miR-31-5p and miR-584-5p) to the 3′ UTR of AGT [19]. However, miRNA function was not directly affected by lead exposure.

Our study had some specific limitations. First, sample sizes were small, particularly for the lead poisoning group, and more samples may serve to clarify our results. Second, due to the lack of samples, it was impossible to identify the association between the AGT SNP and miRNA binding in the lead-poisoned group. Third, AGT activity detection might be more convictive. Future work with larger sample sizes should focus on the function of rs7079 to clarify its specific involvement in lead poisoning.

**Conclusions**

This population-based case-control study indicated that the presence of the rs7079 A allele in 3′ UTR of the **Table 2** Angiotensinogen gene (AGT) rs7079 allele frequencies in the lead-exposed and unexposed (control) population, and the association of these polymorphisms with lead exposure

| Genotypes | BLL1\(^a\) (n = 190) | BLL2\(^b\) (n = 114) | P \(^c\) | Crude OR (95% CI) | Adjusted OR (95% CI) \(^d\) |
|-----------|---------------------|---------------------|-------|-----------------|----------------------------|
| rs7079    |                     |                     |       |                 |                           |
| CC        | 100                 | 76                  | 0.04  | 1.00            | 1.00                       |
| CA        | 88                  | 36                  |       | 1.86 (1.14–3.03) | 2.27 (1.33–3.86)           |
| AA        | 2                   | 2                   |       | 0.76 (0.11–5.52) | 0.93 (0.12–7.31)           |
| CA + AA   | 90                  | 38                  | 0.02  | 1.80 (1.11–2.92) | 1.92 (1.16–3.18)           |
| A Allele  | 92                  | 92                  | 0.08  |                 |                           |

The observed genotype frequency among the control subjects was in agreement with Hardy-Weinberg equilibrium (p\(^2\) + 2pq + q\(^2\) = 1) (\(\chi^2 = 0.954, P = 0.329\) for rs7079

\(^a\) Blood lead level (BLL) < 200 μg/L.

\(^b\) Blood lead level (BLL) ≥ 400 μg/L.

\(^c\) Two-sided \(\chi^2\) test for either genotype or allele frequency.

\(^d\) Obtained from logistic regression models adjusted for age, sex, and smoking habits.

![Fig. 1 Difference in serum angiotensinogen (AGT) concentration in individuals with the AGT rs7079 CC genotype (n = 23) and those with the AGT rs7079 CA genotype (n = 16), measured with an enzyme linked immunosorbent assay (ELISA). Bars represent means ± standard deviations. * P = 0.01](image-url)
**AGT** gene significantly increased the risk of lead poisoning. The rs7079 C to A substitution weakened the binding between miR-31-5p/miR-584-5p and the 3′ UTR of **AGT**, possibly increasing **AGT** expression and, consequently, altering the risk of lead poisoning.

**Abbreviations**

3′ UTR: 3′ untranslated region; **AGT**: Angiotensinogen; BLLs: Blood lead levels; CI: Confidence interval; ELISA: Enzyme linked immunosorbent assay; OR: Odds ratio; PCR: Polymerase chain reaction; SNP: Single nucleotide polymorphism

**Acknowledgements**

This study was funded by the National Natural Science Foundation of China [grant number 81602833], Young medical key talents of Jiangsu Provincial Commission of Health and Family Planning [grant number QNRC2016172] and Wuxi Strong Health Engineering Project [FZXK007].

**Funding**

This study was funded by the National Natural Science Foundation of China [grant number 81602833], Young medical key talents of Jiangsu Provincial Commission of Health and Family Planning [grant number QNRC2016172] and Wuxi Strong Health Engineering Project [FZXK007].

**Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

LC and WY conceived the idea of this study. HNK collected samples. WM, SN, and ZJ performed lab works. WY and LC wrote the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of Wuxi Center for Disease Control and Prevention.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Wuxi Medical School, Jiangnan University, 499 Jincheng Rd, Wuxi 214023, People’s Republic of China. 2Department of Occupational Health, Wuxi Center for Disease Control and Prevention, Wuxi, China.

**Received**: 12 October 2018 **Accepted**: 20 January 2019 **Published online**: 26 January 2019

**References**

1. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res. 2006;99(7):692–705.

2. Simoes MR, Ribeiro Junior RF, Vescovi MV, de Jesus HC, Padilha AS, Stefanon I, Vassallo DV, Sálaices M, Fiorese M. Acute lead exposure increases arterial pressure: role of the renin-angiotensin system. PLoS One. 2011;6(4):e18730.

3. Kim HK, Lee H, Kwon JT, Kim HJ. A polymorphism in **AGT** and **AGTR1** gene is associated with lead-related high blood pressure. J Renin Angiotensin Aldosterone Syst. 2013;16(4):712–9.

4. Grindeling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87(6):1816–28.

5. Luft FC. Molecular genetics of human hypertension. J Hypertens. 1998;16(12 Pt 2):1871–8.

6. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lafou T, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71(1):169–80.

7. Kim HS, Kgee JH, Kluckman KD, Hagaman JR, Hodgen JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995;92(7):2735–9.

8. Vander AJ. Chronic effects of lead on the renin-angiotensin system, Environ Health Perspect. 1988;78:77–83.

9. Sharafi AM, Darabi R, Akbarloo N, Lariani B, Khoshbaten A. Investigation of molecular mechanisms underlying lead-related hypertension. Toxicol Lett. 2004;153(2):233–8.

10. Weiler E, Khalil-Manesh F, Gonick HC. Effects of lead and a low-molecular-weight endogenous plasma inhibitor on the kinetics of sodium-potassium-activated adenosine triphosphatase and potassium-activated p-nitrophenylphosphatase. Clin Sci (Lond). 1990;79(2):185–92.

11. Grzuza LT, Cordellini S. Perinatal lead exposure affects nitric oxide and cyclooxygenase pathways in aorta of weaned rats. Toxicol Sci. 2008;103(1):207–14.

12. Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;295(2):H434–65.
13. Farmand F, Ehdai A, Roberts CK, Sindhu RK. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environ Res. 2005;98(1):33–9.

14. Su X, Lee L, Li X, Lv J, Hu Y, Zhan S, Cao W, Mei L, Tang YM, Wang D, Krauss RM, Taylor KD, Rotter JL, Yang H. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation. 2007;115(6):725–32.

15. Ono M, Ochi T, Munekage K, Ogawasara M, Hirose A, Nozaki Y, Takahashi M, Okamoto N, Saihara T. Angiotensinogen gene haplotype is associated with the prevalence of Japanese non-alcoholic steatohepatitis. Hepatol Res. 2011;41(2):123–9.

16. Al-Najai M, Muya P, Tahir AL, Elhawari S, Gueco D, Andres E, Mazhar N, Altassan N, Alshahid M, Dzimiri N. Association of the angiotensinogen gene polymorphism with atherosclerosis and its risk traits in the Saudi population. BMC Cardiovasc Disord. 2013;13:17. https://doi.org/10.1186/1471-2261-13-17.

17. Machal J, Novák J, Hovza R, Zlamal F, Farkaš A, Slaby O, Bienia-Vasku J. Polymorphism in miR-31 and miR-584 binding site in the angiotensinogen gene differentially influences body fat distribution in both sexes. Genes Nutr. 2015;10(5):488.

18. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.

19. Mopidevi B, Ponnala M, Kumar A. Human angiotensinogen +11525 C/a polymorphism modulates its gene expression through microRNA binding. Physiol Genomics. 2013;45(19):901–6.

20. Li C, Xu M, Wang S, Yang X, Zhou S, Zhang J, Liu Q, Sun Y. Lead exposure upregulated miRNA-21 expression by increasing methylation level of the promoter CpG islands. Toxicol Lett. 2011;203(1):48–53.

21. Piliner JR, Hu H, Ettinger A, Sanchez BN, Wright RO, Cantonwine D, Lazarus A, Lamadrid- Figueroa H, Mercado-Garcia A, Tellez-Rojo MM, Hernandez-Avila M. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. Environ Health Perspect. 2009;117(9):1146–71.

22. Sanders AP, Burris HH, Just AC, Motta V, Amarasiriwardena C, Svensson K, Oken E, Solano-Gonzalez M, Mercado-Garcia A, Panico I, Schwartz J, Tellez-Rojo MM, Baccarelli AA, Wright RO. Altered miRNA expression in the cervix during pregnancy associated with lead and mercury exposure. Epigenomics. 2015;7(6):885–96.

23. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis. 2008;29(7):1306–11.

24. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease—a systematic review. Environ Health Perspect. 2007;115(3):472–82.

25. Iso H, Harada S, Shimamoto T, Sato S, Kitamura A, Sankai T, Tanigawa T, Iida M, Komachi Y. Angiotensinogen T174M and M235T variants, sodium intake and hypertension among non-drinking, lean Japanese men and women. J Hypertens. 2000;18(9):1197–206.

26. Schmidt R, Schmidt H, Fazekas F, Launer LJ, Niederkorn K, Kapeller P, Lechner A, Kostner GM. Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. Hypertension. 2001;38(1):110–5.

27. Pereira AC, Mota GF, Cunha RS, Herbenhoff FL, Mill JG, Krieger JE. Angiotensinogen 235T allele “dosage” is associated with blood pressure phenotypes. Hypertension. 2003;41(1):25–30.

28. Wu SJ, Chiang FT, Chen WJ, Liu PH, Hsu KL, Hwang JJ, Lai LP, Lin JL, Tseng CD, Tseng YZ. Three single-nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: single locus genotyping vs. haplotype analysis. Physiol Genomics. 2004;17(2):79–86.

29. Jiao J, Wang M, Wang Y, Sun N, Li C. Lead exposure increases blood pressure by increasing angiotensinogen expression. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2016;51(5):634–9.

30. Chowdhury R, Shah D, Payal AR. Healthy worker effect phenomenon: revisited with emphasis on statistical methods - a review. Indian J Occup Environ Med. 2017;21(2):12–8.

31. Onalaja AO, Claudio L. Genetic susceptibility to lead poisoning. Environ Health Perspect. 2000;108(Suppl 1):123–8.

32. Weaver VM, Lee BK, Todd AC, Ahn KD, Shi W, Jaar BG, Kelsey KT, Lustberg ME, Silberberg EK, Parsons PJ, Wen J, Schwartz BS. Effect modification by delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase gene polymorphisms on associations between patella lead and renal function in lead workers. Environ Res. 2006;102(1):61–9.